MCP ‐1 as a Biomarker of Vascular Function

BACKGROUND: Endothelial dysfunction and arterial stiffness have been shown to be associated with cardiovascular disease (CVD) outcomes but assessment of these is not straightforward. CVD risk in diabetes shows heterogeneity and new biomarkers are required to stratify CVD risk in these patients. The aim of this study was to determine the association between MCP-1 and measures of endothelial function and large artery stiffness, independently of traditional CVD risk factors, in patients with and without Type 2 diabetes mellitus (T2DM). METHODS: This study analysed the association of monocyte chemoattractant protein-1 (MCP-1) with measures of vascular function in 477 patients with T2DM and 261 patients without T2DM. Endothelium-dependent and endothelium-independent microvascular responses were assessed by measuring vasodilator responses to iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP), respectively, using laser Doppler imaging (LDI). Large artery stiffness was measured using carotid-femoral pulse wave velocity (cf-PWV). RESULTS: MCP-1 was inversely associated with ACh and SNP responses, in patients with and without T2DM. Each SD higher MCP-1 was associated with lower ACh (β = -21.7 AU, 95% CI: -34.3 to -9.0) and SNP (β = -20.5 AU, 95% CI: -32.5 to -8.4) responses after adjustment for CVD risk factors, BMI, HbA1c, eGFR, medication and study centre, with similar associations in patients with and without T2DM. MCP-1 was not associated with the ACh:SNP ratio or with cf-PWV, and the associations were not modified by BMI. CONCLUSION: This study shows MCP-1 to be associated with reduced microvascular vasodilator capacity, affecting endothelium-dependent and endothelium-independent responses, in patients with and without T2DM, independently of adiposity. Longitudinal studies in larger cohorts are required to determine whether MCP-1 improves CVD risk prediction and identifies patients most likely to benefit from targeted therapy.

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2026-11-16
DOI
https://doi.org/10.1111/dom.71544
Primary Topic
Cardiovascular Health and Disease Prevention
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

MCP ‐1 as a Biomarker of Vascular Function

Faisel Khan, William David Strain, Francesco Casanova, Kim M. Gooding et al.
Diabetes Obesity and Metabolism
Cardiovascular Health and Disease Prevention
article

MCP ‐1 as a Biomarker of Vascular Function

Faisel Khan, William David Strain, Francesco Casanova, Kim M. Gooding, Suzy V. Hope, David M. Mawson, Phillip E. Gates, Angela Shore, William MacDonald, Atanu Bhattacharjee, Kunihiko Aizawa, Mark Gilchrist
article en

Abstract

BACKGROUND: Endothelial dysfunction and arterial stiffness have been shown to be associated with cardiovascular disease (CVD) outcomes but assessment of these is not straightforward. CVD risk in diabetes shows heterogeneity and new biomarkers are required to stratify CVD risk in these patients. The aim of this study was to determine the association between MCP-1 and measures of endothelial function and large artery stiffness, independently of traditional CVD risk factors, in patients with and without Type 2 diabetes mellitus (T2DM). METHODS: This study analysed the association of monocyte chemoattractant protein-1 (MCP-1) with measures of vascular function in 477 patients with T2DM and 261 patients without T2DM. Endothelium-dependent and endothelium-independent microvascular responses were assessed by measuring vasodilator responses to iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP), respectively, using laser Doppler imaging (LDI). Large artery stiffness was measured using carotid-femoral pulse wave velocity (cf-PWV). RESULTS: MCP-1 was inversely associated with ACh and SNP responses, in patients with and without T2DM. Each SD higher MCP-1 was associated with lower ACh (β = -21.7 AU, 95% CI: -34.3 to -9.0) and SNP (β = -20.5 AU, 95% CI: -32.5 to -8.4) responses after adjustment for CVD risk factors, BMI, HbA1c, eGFR, medication and study centre, with similar associations in patients with and without T2DM. MCP-1 was not associated with the ACh:SNP ratio or with cf-PWV, and the associations were not modified by BMI. CONCLUSION: This study shows MCP-1 to be associated with reduced microvascular vasodilator capacity, affecting endothelium-dependent and endothelium-independent responses, in patients with and without T2DM, independently of adiposity. Longitudinal studies in larger cohorts are required to determine whether MCP-1 improves CVD risk prediction and identifies patients most likely to benefit from targeted therapy.

Diabetes Obesity and Metabolism
University of Dundee (GB), University of Exeter (GB), Ninewells Hospital (GB), NIHR Exeter Clinical Research Facility (GB)
Good health and well-being
Cardiovascular Health and Disease Prevention
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon